March 5 (Reuters) – Genentech, part of Roche, said on Thursday that its experimental obesity drug helped people lose up to 10.7% of their body weight in a mid-stage study.
In the 493-patient trial, the drug, petrelintide, helped people lose up to 10.7% of their body weight over 42 weeks, far more than the 1.7% seen with a placebo.
Roche gained access to petrelintide through a collaboration and licensing deal signed with Denmark’s Zealand Pharma last year, giving the Swiss drugmaker shared development rights to the amylin‑based obesity therapy.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Alan Barona)
